Matteo Brunelli

Prof. Dr. Matteo Brunelli

Department of Diagnostic and Public Health, Section of Pathology, University of Verona, 37134 Verona, Italy

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2019 in Cancers
Verified
Journal Article
Open access
PDF file
ACAnna Caliò
Anna Caliò
DSDiego Segala
Diego Segala
EMEnrico Munari
Enrico Munari
Matteo BrunelliMatteo Brunelli
Matteo Brunelli
Guido MartignoniGuido Martignoni
Guido Martignoni
The new category of MiT family translocation renal cell carcinoma has been included into the World Health Organization (WHO) classification in 2016. The MiT family translocation renal cell carcinoma comprises Xp11 translocation renal cell carcinoma harboring TFE3 gene fusions and t(6;11) renal cell carcinoma harboring TFEB gene fusion. At the beginning, they were recognized in childhood; nevertheless, it has been demonstrated that these neoplasms can occur in adults as well. In the nineties, among Xp11 renal cell carcinoma, ASPL, PRCC, and SFPQ (PSF) were the first genes recognized as partners in TFE3 rearrangement. Recently, many other genes have been identified, and a wide spectrum of morphologies has been described. For this reason, the diagnosis may be challenging based on the histology, and the differential diagnosis includes the most common renal cell neoplasms and pure epithelioid PEComa/epithelioid angiomyolipoma of the kidney. During the last decades, many efforts have been made to identify immunohistochemical markers to reach the right diagnosis. To date, staining for PAX8, cathepsin K, and melanogenesis markers are the most useful identifiers. However, the diagnosis requires the demonstration of the chromosomal rearrangement, and fluorescent in situ hybridization (FISH) is considered the gold standard. The outcome of Xp11 translocation renal cell carcinoma is highly variable, with some patients surviving decades with indolent disease and others dying rapidly of progressive disease. Despite most instances of t(6;11) renal cell carcinoma having an indolent clinical course, a few published cases demonstrate aggressive behavior. Recently, renal cell carcinomas with TFEB amplification have been described in connection with t(6;11) renal cell carcinoma. Those tumors appear to be associated with a more aggressive clinical course. For the aggressive cases of MiT family translocation carcinoma, the optimal therapy remains to be determined; however, new target therapies seem to be promising, and the search for predictive markers is mandatory.

Verified
Journal Article
Open access
PDF file
EMEnrico Munari
Enrico Munari
Francesca Romana MariottiFrancesca Romana Mariotti
Francesca Romana Mariotti
LQLinda Quatrini
Linda Quatrini
PBPietro Bertoglio
Pietro Bertoglio
NTNicola Tumino
Nicola Tumino
Lorenzo MorettaLorenzo Moretta
Lorenzo Moretta
Immune evasion is a key strategy adopted by tumor cells to escape the immune system while promoting their survival and metastatic spreading. Indeed, several mechanisms have been developed by tumors to inhibit immune responses. PD-1 is a cell surface inhibitory receptor, which plays a major physiological role in the maintenance of peripheral tolerance. In pathological conditions, activation of the PD-1/PD-Ls signaling pathway may block immune cell activation, a mechanism exploited by tumor cells to evade the antitumor immune control. Targeting the PD-1/PD-L1 axis has represented a major breakthrough in cancer treatment. Indeed, the success of PD-1 blockade immunotherapies represents an unprecedented success in the treatment of different cancer types. To improve the therapeutic efficacy, a deeper understanding of the mechanisms regulating PD-1 expression and signaling in the tumor context is required. We provide an overview of the current knowledge of PD-1 expression on both tumor-infiltrating T and NK cells, summarizing the recent evidence on the stimuli regulating its expression. We also highlight perspectives and limitations of the role of PD-L1 expression as a predictive marker, discuss well-established and novel potential approaches to improve patient selection and clinical outcome and summarize current indications for anti-PD1/PD-L1 immunotherapy.

Verified
Journal Article
Open access
PDF file
SMStefano Marletta
Stefano Marletta
Nicola FuscoNicola Fusco
Nicola Fusco
EMEnrico Munari
Enrico Munari
Claudio LuchiniClaudio Luchini
Claudio Luchini
ALESSIA CIMADAMOREALESSIA CIMADAMORE
ALESSIA CIMADAMORE
Albino EccherAlbino Eccher
Albino Eccher
Background. Innovative drugs targeting the PD1/PD-L1 axis have opened promising scenarios in modern cancer therapy. Plenty of assays and scoring systems have been developed for the evaluation of PD-L1 immunohistochemical expression, so far considered the most reliable therapeutic predictive marker. Methods. By gathering the opinion of acknowledged experts in dedicated fields of pathology, we sought to update the currently available evidence on PD-L1 assessment in various types of tumors. Results. Robust data were progressively collected for several anatomic districts and leading international agencies to approve specific protocols: among these, TPS with 22C3, SP142 and SP263 clones in lung cancer; IC with SP142 antibody in breast, lung and urothelial tumors; and CPS with 22C3/SP263 assays in head and neck and urothelial carcinomas. On the other hand, for other malignancies, such as gastroenteric neoplasms, immunotherapy has been only recently introduced, often for particular histotypes, so specific guidelines are still lacking. Conclusions. PD-L1 immunohistochemical scoring is currently the basis for allowing many cancer patients to receive properly targeted therapies. While protocols supported by proven data are already available for many tumors, dedicated studies and clinical trials focusing on harmonization of the topic in other still only partially explored fields are surely yet advisable.

6 November 2015 in Targeted Oncology
Verified
Journal Article
Closed access
PDF file
Francesco MassariFrancesco Massari
Francesco Massari
CCChiara Ciccarese
Chiara Ciccarese
ACAnna Caliò
Anna Caliò
EMEnrico Munari
Enrico Munari
LCLuca Cima
Luca Cima
Matteo BrunelliMatteo Brunelli
Matteo Brunelli

1 May 2014 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
ACAnna Caliò
Anna Caliò
ANAlessia Nottegar
Alessia Nottegar
EGEliana Gilioli
Eliana Gilioli
EBEmilio Bria
Emilio Bria
SPSara Pilotto
Sara Pilotto
Matteo BrunelliMatteo Brunelli
Matteo Brunelli

18 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
ACAnna Caliò
Anna Caliò
Matteo BrunelliMatteo Brunelli
Matteo Brunelli
SGStefano Gobbo
Stefano Gobbo
PAPedram Argani
Pedram Argani
EMEnrico Munari
Enrico Munari
Guido MartignoniGuido Martignoni
Guido Martignoni
Cathepsin K is a papain-like cysteine protease with high matrix-degrading activity. Among several cathepsins, cathepsin K is the most potent mammalian collagenase, mainly expressed by osteoclasts. This review summarizes most of the recent findings of cathepsin K expression, highlighting its role in renal tumors for diagnostic purposes and as a potential molecular target. Indeed, cathepsin K is a recognized diagnostic tool for the identification of TFE3/TFEB-rearranged renal cell carcinoma, TFEB-amplified renal cell carcinoma, and pure epithelioid PEComa/epithelioid angiomyolipoma. More recently, its expression has been observed in a subgroup of eosinophilic renal neoplasms molecularly characterized by TSC/mTOR gene mutations. Interestingly, both TSC mutations or TFE3 rearrangement have been reported in pure epithelioid PEComa/epithelioid angiomyolipoma. Therefore, cathepsin K seems to be a downstream marker of TFE3/TFEB rearrangement, TFEB amplification, and mTOR pathway activation. Given the established role of mTOR inhibitors as a pharmacological option in renal cancers, cathepsin K could be of use as a predictive marker of therapy response and as a potential target. In the future, uropathologists may implement the use of cathepsin K to establish a diagnosis among renal tumors with clear cells, papillary architecture, and oncocytic features.